Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02463877 · ClinicalTrials.gov registry record · Phase 2

A Minimally-invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy

A Phase 2 study, sponsored by University of California, San Diego.

Completed
Registry status
Phase 2
Development phase
18
Enrollment target

NCT02463877 is a Phase 2 study that has completed, run by University of California, San Diego. The registered enrollment target is 18 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02463877, a Phase 2 study, has completed, sponsored by University of California, San Diego.

COMPLETED
Registry status
Phase 2
Development phase
18 participants
Enrollment target

Study Summary

The purpose of this study is to determine the feasibility of surgical techniques involving minimal entry into the living body approach for tumor reduction and treatment in which highly concentrated anticancer drugs are put directly into the abdomen through a tubes (HIPEC), and to determine if this approach may improve short-term postoperative outcomes, including the development of complications related to surgery within the first 30 days after surgery. Participation in this study is entirely voluntary. Approximately 30 subjects will take part in this single-center study and all will be enrolled at University of California San Diego.

Interventions

  • PROCEDURE Minimally-Invasive Procedure

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2014-10
Est. Completion 2022-04-30
Phase Phase 2

Sponsor

University of California, San Diego

775 total trials

What the Registry Record Tells You About NCT02463877

The ClinicalTrials.gov registry entry for NCT02463877 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Minimally-Invasive Procedure is the first listed.

NCT02463877 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02463877 about?

NCT02463877 is a clinical study titled "A Minimally-invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy". The purpose of this study is to determine the feasibility of surgical techniques involving minimal entry into the living body approach for tumor reduction and treatment in which highly concentrated anticancer drugs are put directly into the abdomen through a tubes (HIPEC), and to determine if this a...

What is the current status of trial NCT02463877?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2014-10. Estimated completion is 2022-04-30.

What interventions are being tested in trial NCT02463877?

The interventions under investigation include: Minimally-Invasive Procedure (PROCEDURE).

Who is sponsoring clinical trial NCT02463877?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.